Clinical trials: Sitagliptin
Type 2 Diabetes Mellitus
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.
- Trial name
- NCT00888238
- Testing
- sitagliptin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis, Prediabetes
Prevention of Cystic Fibrosis Diabetes
Acute systemic hyperglycemia causes oxidative stress and a pro-inflammatory response. The pro-inflammatory cytokines induced by hyperglycemia are toxic to islet insulin producing cells, and thus worsen glucose intolerance.
- Trial name
- Prevent (NCT00967798)
- Testing
- Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2, Hyperglycemia
Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will receive Sitagliptin or placebo.
- Trial name
- NCT01970462
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kathleen Dungan
HIV-1 Infection
Sitagliptin for Reducing Inflammation and Immune Activation
The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin) reduces inflammation and immune activation markers in HIV-infected men and women when compared to a placebo (inactive…
- Trial name
- NCT02513771
- Testing
- Sitagliptin
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Type 2 Diabetes
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in…
- Trial name
- NCT02284893
- Testing
- Saxagliptin, Dapagliflozin, Sitagliptin
- Where
- 79 sites in United States, Hungary and 4 more
- Volunteers
- 461 people
- Sponsor
- AstraZeneca
Obesity
Effect of DPP4 Inhibition on Growth Hormone Secretion
This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH)…
- Trial name
- NCT01701973
- Testing
- Sitagliptin, Pegvisomant, L-NMMA
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Inflammation, Macrophage Infiltration
Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation
People living with human immunodeficiency virus infection (HIV) have 2-4fold greater risk for developing diabetes and heart disease than the general population.
- Conditions
- Inflammation, Macrophage Infiltration, Cardiovascular Disease
- Trial name
- NCT01552694
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Pre-diabetes, Impaired Fasting Glucose
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
- Conditions
- Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
- Trial name
- NCT01488279
- Testing
- Dexamethasone 2.5 mg and Sitagliptin 100 mg
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Coronary Artery Disease
Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery
The purpose of this study is to compare sitagliptin and placebo for the prevention of high blood glucose during surgery.
- Trial name
- SITACABG NonDM (NCT02443402)
- Testing
- Sitagliptin, Regular Human Insulin, Insulin glargine
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Emory University
Disorder of Glucose Regulation
Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Gestational diabetes mellitus (GDM) is defined as "any degree of glucose intolerance with onset or first recognition during pregnancy." GDM is one of the most frequent metabolic disorders occurring during pregnancy.
- Trial name
- NCT01856907
- Testing
- Sitagliptin-Metformin, Metformin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Woman's
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
- Trial name
- NCT01119846
- Testing
- GSK1292263, Sitagliptin
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
This study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2330672 compared to sitagliptin when administered with metformin for 14 days to subjects with type 2 diabetes…
- Trial name
- NCT02202161
- Testing
- GSK2330672, Sitagliptin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
This proposal is to fund a pilot study to assess feasibility and refine methodology for an intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD).
- Trial name
- ROAD (NCT00780715)
- Testing
- Gliclazide MR, Sitagliptin, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University of Dundee
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.
- Trial name
- NCT01376323
- Testing
- GSK256073 1mg, GSK256073 5mg, GSK256073 10mg
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset…
- Trial name
- REPAIR-T1D (NCT01155284)
- Testing
- Sitagliptin and Lansoprazole
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Type 2 Diabetes, Microalbuminuria
Use of Sitagliptin to Decrease Microalbuminuria
The people being asked to participate in this study have type 2 diabetes and abnormal levels of protein in their urine. This indicates that they are starting to develop diabetic kidney disease.
- Trial name
- NCT02048904
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Missouri-Columbia
Type 2 Diabetes Mellitus
Changes in Bone Turnover With Increased Incretin Hormone Exposure
The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.
- Trial name
- DRTC (NCT01374568)
- Testing
- sitagliptin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glucose Homeostasis
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly…
- Trial name
- NCT00947011
- Testing
- Januvia
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University